Skip to content
DraconiticResearch
Search Sources API
220,430 studies31 sourcesUpdated 2 min ago
Peer-reviewedLicence not statedInternational Journal of Radiation Oncology*Biology*Physics

Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death Ligand-1–High Locally Advanced Non-small Cell Lung Cancer

  • Steven Hsesheng Lin1
  • Stephanie L. Pugh2
  • Diane Marie Del Valle3
  • Vladimir Roudko3
  • Martin Joseph Edelman4
  • Anthony Doemer5
  • Charles B. Simone6
  • Kai Nie3
  • Tia Rizakos3
  • Alisha Mugunthan3
  • Ruihua Zhang3
  • Geoffrey Kelly3
17 more authors
  • Noam Beckmann3
  • Ryan C. Thompson3
  • Seunghee Kim‐Schulze3
  • Edgar Gonzalez‐Kozlova3
  • Saumil J. Gandhi7
  • Sai Bikkina8
  • Nagla Abdel Karim9
  • Xinglei Shen10
  • Shahed S Badiyan11
  • Kristin A. Higgins12
  • Arnab Chakravarti13
  • Maria Werner‐Wasik14
  • John M. Schallenkamp15
  • Mayte Suárez‐Fariñas3
  • Sacha Gnjatic3
  • Anne S. Tsao16
  • Jeffrey D. Bradley17
17 affiliations
  1. 1Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: [email protected]
  2. 2NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
  3. 3Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York
  4. 4Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
  5. 5Department of Radiation Oncology, Henry Ford Cancer Institute, Detroit, Michigan
  6. 6Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center and the New York Proton Center, New York, New York
  7. 7Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
  8. 8Department of Radiation Oncology, Karmanos Cancer Institute at McLaren Lapeer Region, Lapeer, Michigan
  9. 9Department of Radiation Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia
  10. 10Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas
  11. 11Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas
  12. 12Department of Radiation Oncology, City of Hope Cancer Center, Atlanta, Georgia
  13. 13Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
  14. 14Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
  15. 15Department of Radiation Oncology, Billings Clinic Cancer Center (Accrual for Montana Cancer Consortium NCORP), Billings, Montana
  16. 16Departments of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
  17. 17Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania
Open at sourceDOICite

Related

  1. 482 Biomarker analysis from KESTREL identifies tumor cytotoxicity and immunogenic cell death as predictors of benefit with durvalumab plus tremelimumab in HNSCC
    Qing Wu, Flavia Michelini, Hung-Ying Lin +2
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. Immune-programmed cell death crosstalk implicates plasma sTNFR1 as a candidate biomarker for sepsis-associated encephalopathy
    Che Wang, Tong Xin, Yifei Chen +6
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMCPMC
  3. Clinical Outcomes and Safety of Spatially Fractionated Radiotherapy for Malignant Tumors: A Systematic Review and Evidence Map
    Nandan M Shanbhag, Abdulrahman Bin Sumaida, Khalid S Balaraj
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Combination therapy using durvalumab in patients with advanced soft tissue sarcoma: is doxorubicin best?
    Tomoki Nakamura, Masahiro Hasegawa
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  5. Prognostic impact of immune-related adverse events in non-completers of durvalumab consolidation therapy for non-small cell lung cancer: a single-center retrospective cohort study
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{lin2026safety,
  title = {{Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death Ligand-1–High Locally Advanced Non-small Cell Lung Cancer}},
  author = {Steven Hsesheng Lin and Stephanie L. Pugh and Diane Marie Del Valle and Vladimir Roudko and Martin Joseph Edelman and Anthony Doemer and Charles B. Simone and Kai Nie and Tia Rizakos and Alisha Mugunthan and Ruihua Zhang and Geoffrey Kelly and Noam Beckmann and Ryan C. Thompson and Seunghee Kim‐Schulze and Edgar Gonzalez‐Kozlova and Saumil J. Gandhi and Sai Bikkina and Nagla Abdel Karim and Xinglei Shen and Shahed S Badiyan and Kristin A. Higgins and Arnab Chakravarti and Maria Werner‐Wasik and John M. Schallenkamp and Mayte Suárez‐Fariñas and Sacha Gnjatic and Anne S. Tsao and Jeffrey D. Bradley},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  month = sep,
  doi = {10.1016/j.ijrobp.2026.08.075},
  url = {https://pmc.ncbi.nlm.nih.gov/articles/PMC13618747/},
}
RIS
TY  - JOUR
TI  - Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death Ligand-1–High Locally Advanced Non-small Cell Lung Cancer
AU  - Steven Hsesheng Lin
AU  - Stephanie L. Pugh
AU  - Diane Marie Del Valle
AU  - Vladimir Roudko
AU  - Martin Joseph Edelman
AU  - Anthony Doemer
AU  - Charles B. Simone
AU  - Kai Nie
AU  - Tia Rizakos
AU  - Alisha Mugunthan
AU  - Ruihua Zhang
AU  - Geoffrey Kelly
AU  - Noam Beckmann
AU  - Ryan C. Thompson
AU  - Seunghee Kim‐Schulze
AU  - Edgar Gonzalez‐Kozlova
AU  - Saumil J. Gandhi
AU  - Sai Bikkina
AU  - Nagla Abdel Karim
AU  - Xinglei Shen
AU  - Shahed S Badiyan
AU  - Kristin A. Higgins
AU  - Arnab Chakravarti
AU  - Maria Werner‐Wasik
AU  - John M. Schallenkamp
AU  - Mayte Suárez‐Fariñas
AU  - Sacha Gnjatic
AU  - Anne S. Tsao
AU  - Jeffrey D. Bradley
PY  - 2026
DA  - 2026/09/01
JO  - International Journal of Radiation Oncology*Biology*Physics
DO  - 10.1016/j.ijrobp.2026.08.075
UR  - https://pmc.ncbi.nlm.nih.gov/articles/PMC13618747/
SN  - 0360-3016
SN  - 1879-355X
ER  -